J&J to buy Intra-Cellular Therapies in $14.6B deal

Johnson & Johnson announced on Monday that it reached an agreement to buy biopharmaceutical company Intra-Cellular Therapies Inc. for around $14.6 billion or $132 per share in cash. J&J said i…